- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07582029
Ultrasound-Guided Rectus Sheath Block Versus Local Infiltration
Comparison of the Analgesic Effects of Local Anesthetic Infiltration and Ultrasound-Guided Rectus Sheath Block in Laparoscopic Cholecystectomy Operations: A Prospective Randomized Controlled Study
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Laparoscopic cholecystectomy is a very commonly performed and painful surgical procedure. The etiology of pain is complex and commonly includes pain related to trocar insertion sites, pain secondary to carbon dioxide insufflation, visceral pain, and shoulder pain. Various analgesic medications and regional anesthesia techniques are used for postoperative pain management. Abdominal wall blocks are frequently utilized to reduce opioid-related adverse effects.
Rectus sheath block is a regional anesthesia technique that blocks the anterior cutaneous branches of the lower thoracic nerves (T7-T12) and is used for analgesia in laparoscopic surgeries. Several studies have demonstrated that local anesthetic infiltration provides effective analgesia in laparoscopic cholecystectomy. Although rectus sheath block is an old technique traditionally used in midline surgeries, its analgesic use in laparoscopic procedures has increased in recent years.
In this prospective randomized clinical trial, we aimed to compare the effects of Local Anesthetic Infiltration and Rectus Sheath Block on opioid consumption and pain scores in laparoscopic gallbladder surgery.
To compare the effects of Local Anesthetic Infiltration and Rectus Sheath Block on opioid consumption and pain scores in laparoscopic gallbladder surgery.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: MUSTAFA ALTINAY
- Numéro de téléphone: 05333914422
- E-mail: m_altinay@yahoo.com
Sauvegarde des contacts de l'étude
- Nom: LEYLA KILINC
- Numéro de téléphone: +90 532 417 02 44
- E-mail: leylaturkoglu@hotmail.com
Lieux d'étude
-
-
-
Istanbul, Turquie (Türkiye), 34371
- Sisli Hamidiye Etfal Training Hospital
-
Contact:
- MUSTAFA ALTINAY
- Numéro de téléphone: 05333914422
- E-mail: m_altinay@yahoo.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- ASA (American Society of Anesthesiologists) class I-II patients
- Patients aged between 18 and 65 years
- Patients undergoing laparoscopic cholecystectomy surgery
Exclusion Criteria:
- ASA class III-IV patients
- Patients undergoing emergency surgery
- Relatives of patients who do not provide consent
- Presence of chronic pain
- Chronic opioid use
- Presence of local anesthetic allergy
- Ibuprofen allergy
- Paracetamol allergy
- Presence of infection at the block site
- Coagulopathy
- Increased intracranial pressure
- Pre-existing neurological deficit
- Severe organ failure
- Mental retardation
- Anatomical deformity
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: GROUP RSB
Rectus Sheath Block: After completion of the operation, during the surgical closure phase, bilateral rectus sheath block will be performed. A linear ultrasound probe will be placed transversely over the umbilicus and 1 cm lateral to it. After visualization of the rectus abdominis muscle and posterior rectus sheath, a 22-Gauge 80 mm block needle (Braun Stimuplex Ultra-360, Melsungen, Germany) will be advanced from lateral to medial using the in-plane technique. Following hydrodissection with 1 mL saline between the rectus muscle and posterior sheath and confirmation of appropriate spread, 20 mL local anesthetic (0.25% bupivacaine) will be administered with intermittent negative aspiration. |
After completion of the operation, during the surgical closure phase, bilateral rectus sheath block will be performed.
A linear ultrasound probe will be placed transversely over the umbilicus and 1 cm lateral to it.
After visualization of the rectus abdominis muscle and posterior rectus sheath, a 22-Gauge 80 mm block needle (Braun Stimuplex Ultra-360, Melsungen, Germany) will be advanced from lateral to medial using the in-plane technique.
Following hydrodissection with 1 mL saline between the rectus muscle and posterior sheath and confirmation of appropriate spread, 20 mL local anesthetic (0.25% bupivacaine) will be administered with intermittent negative aspiration.
|
|
Comparateur actif: GROUP LAI
Local Anesthetic Infiltration: At the end of the operation, the surgeon will infiltrate 5 mL local anesthetic (0.5% bupivacaine) subcutaneously into each of the four trocar insertion sites. |
At the end of the operation, the surgeon will infiltrate 5 mL local anesthetic (0.5% bupivacaine) subcutaneously into each of the four trocar insertion sites.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
NRS Score
Délai: Pain scores will be assessed and recorded at postoperative 0, 1, 4, 12, and 24 hours.
|
Postoperative pain assessment will be performed using the Numeric Rating Scale (NRS).
The NRS is a scale in which patients rate their pain intensity numerically from 0 (no pain) to 10 (worst imaginable pain).
|
Pain scores will be assessed and recorded at postoperative 0, 1, 4, 12, and 24 hours.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Opioid Consumption
Délai: 24 hour
|
Postoperative opioid consumption will be evaluated using intravenous patient-controlled analgesia (IV PCA) over 24 hours.
PCA will be set in bolus-only mode (10 mg tramadol), without continuous infusion.
Patients will be educated preoperatively regarding PCA use and instructed to administer boluses in case of pain.
At the end of 24 hours, total opioid consumption will be recorded from the device data, and the time to first bolus administration (time to first analgesic requirement) will also be evaluated.
|
24 hour
|
|
Adverse Effects
Délai: 24 hour
|
Adverse effects such as hypotension, bradycardia, nausea, vomiting, and local anesthetic systemic toxicity (LAST) occurring within the first 24 postoperative hours will be monitored and recorded.
|
24 hour
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: LEYLA KILINC, şişli etfal eğitim araştırma hastanesi
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Complications postopératoires
- Processus pathologiques
- Maladies du système digestif
- Maladies des voies biliaires
- Maladies de la vésicule biliaire
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Douleur, Postopératoire
- Cholécystite
- Lithiase biliaire
Autres numéros d'identification d'étude
- zeynep-1
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .